## Integrin $\alpha 6$ variants and colorectal cancer

I read with interest the study by De Archangelis *et al*<sup>1</sup> on the protective role of hemidesmosomes against colitis and colorectal cancer using genetically modified mouse integrin a6 subunit mutant models. I was however surprised to read that, based on their observations with these  $\alpha 6$  mutant mice, the authors concluded that the  $\alpha 6\beta 4$  integrin can be classified as a tumour suppressor in the colon. Indeed, earlier studies have reported that in carcinomas,  $\alpha 6\beta 4$  can be released from hemidesmosomes to become associated with microfilament-associated cell motility adhesomes and, consequently, engage in various signal transduction pathways that contribute to tumour progression.<sup>2</sup> <sup>3</sup> While it is recognised that the roles of  $\alpha 6\beta 4$  may be dependent on the tissue-context as underlined by the authors, it remains increasingly evident that the alternative messenger RNA splicing of the  $\alpha 6$ subunit constitutes a key-contributing factor for the definition of the function of  $\alpha 6\beta 4$  in determining the fate of cancer cells,<sup>4</sup> including colorectal cancer cells.<sup>5</sup>

First, it is noteworthy that both  $\alpha 6$  subunits are normally expressed in the




Figure 1 Schematic view of the colonic epithelium showing the differential expression of integrin  $\alpha 6\beta 4$  forms in the normal mucosa and in tumours. Under normal conditions, the  $\alpha 6A$  subunit is located in the proliferative cells of the gland while  $\alpha 6B$  is confined to the quiescent upper gland and surface epithelial cells.<sup>5</sup> In colorectal tumours, total  $\alpha 6\beta 4$  expression increases as its  $\alpha 6A\beta 4$  form.<sup>5 8</sup>

intestinal epithelium but in distinct compartments, a6A being found in the proliferative cells of the glands in both the small and large intestine while  $\alpha 6B$ is restricted to the quiescent/differentiated cells located on the villus and surface epithelium (figure 1).<sup>5 6</sup> Second, the expression of the  $\alpha 6\beta 4$  receptor is increased in colorectal cancer cells<sup>5</sup><sup>7</sup> and it is in fact its pro-proliferative  $\alpha 6A\beta 4$ form that is found to be largely expressed under this context,<sup>8</sup> whereas its  $\alpha 6B\beta 4$ counterpart appears to exert antipro-liferative influences.<sup>5</sup> Altogether, these data indicate that  $\alpha 6\beta 4$  performs distinct functions in intestinal and colonic cells according to the specific  $\alpha 6$  (A or B) splicing variant that constitutes the heterodimeric receptor.

In relation to these previously reported observations, one should also consider the likelihood that an abolition/loss of the  $\alpha 6\beta 4$  heterodimer in the

gut epithelium favours compensatory cell-matrix interactions through other receptors such as the pro-proliferative 37/67-laminin receptor<sup>9</sup> and other previously identified pro-proliferative integrins,<sup>10</sup> which, singly or in combination, may contribute to the complex phenotype that has been observed in the experimental mouse mutant models described.<sup>1</sup>

In this context, the colon tumorigenesis observed in mice carrying a total gut epithelial-specific deletion of the  $\alpha 6$  integrin subunits may need to be interpreted with caution.

## Jean-François Beaulieu Beaulieu

Laboratory of Intestinal Physiopathology, Department of Anatomy & Cell Biology,, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada

**Correspondence to** Prof Jean-François Beaulieu, Laboratory of Intestinal Physiopathology, Room 9425, Department of Anatomy & Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada; jean-francois.beaulieu@usherbrooke.ca

Acknowledgements The author thanks Professor Pierre Vachon for the critical reading of the manuscript and suggestions and Elizabeth Herring for corrections.

**Funding** The original work was funded by the Canadian Institutes of Health Research grants MOP-97836 and MOP-123415 and the Canada Research Chair in Intestinal Physiopathology.

Competing interests None declared.

**Provenance and peer review** Not commissioned; internally peer reviewed.



**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/4.0/

 $\ensuremath{\mathbb{C}}$  Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All

rights reserved. No commercial use is permitted unless otherwise expressly granted.



To cite Beaulieu J-F. Gut 2018;67:1747-1748.

Received 5 October 2017 Revised 13 October 2017 Accepted 18 October 2017 Published Online First 28 October 2017



http://dx.doi.org/10.1136/gutjnl-2015-310847

*Gut* 2018;**67**:1747–1748. doi:10.1136/gutjnl-2017-315415

## REFERENCES

- De Arcangelis A, Hamade H, Alpy F, et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut 2017;66:1748–60.
- 2 Ramovs V, Te Molder L, Sonnenberg A. The opposing roles of laminin-binding integrins in cancer. *Matrix Biol* 2017;57-58:213–43.
- 3 Stewart RL, O'Connor KL. Clinical significance of the integrin  $\alpha 6\beta 4$  in human malignancies. Lab Invest 2015;95:976–86.
- 4 Goel HL, Gritsko T, Pursell B, *et al*. Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells. *Cell Rep* 2014;7:747–61.
- 5 Dydensborg AB, Teller IC, Groulx JF, et al. Integrin alpha6Bbeta4 inhibits colon cancer cell proliferation and c-Myc activity. *BMC Cancer* 2009;9:223.
- 6 Dydensborg AB, Teller IC, Basora N, et al. Differential expression of the integrins alpha6Abeta4 and alpha6Bbeta4 along the crypt-villus axis in the human small intestine. *Histochem Cell Biol* 2009;131:531–6.
- 7 Ni H, Dydensborg AB, Herring FE, et al. Upregulation of a functional form of the beta4 integrin subunit in colorectal cancers correlates with c-Myc expression. Oncogene 2005;24:6820–9.
- 8 Groulx JF, Giroux V, Beauséjour M, et al. Integrin α6A splice variant regulates proliferation and the Wnt/βcatenin pathway in human colorectal cancer cells. *Carcinogenesis* 2014;35:1217–27.
- 9 Khalfaoui T, Groulx JF, Sabra G, et al. Laminin receptor 37/67LR regulates adhesion and proliferation of normal human intestinal epithelial cells. *PLoS One* 2013;8:e74337.
- 10 Boudjadi S, Bernatchez G, Sénicourt B, *et al.* Involvement of the Integrin  $\alpha 1\beta 1$  in the progression of colorectal cancer. *Cancers* 2017;9:96.